Minimizing the risk of sarcopenic obesity during androgen deprivation therapy-promising results for men treated with GnRH antagonists

Prostate Cancer Prostatic Dis. 2021 Sep;24(3):589-590. doi: 10.1038/s41391-021-00357-w. Epub 2021 Apr 5.

Author

Ilona Csizmadi¹

Affiliation

¹ Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA. ilona.csizmadi@cshs.org.

PMID: 33820952
DOI: 10.1038/s41391-021-00357-w

No abstract available

Publication types

Editorial

MeSH terms

Androgen Antagonists / adverse effects*
Gonadotropin-Releasing Hormone / antagonists & inhibitors*
Humans
Male
Obesity / chemically induced
Obesity / drug therapy*
Obesity / pathology
Prognosis
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / pathology
Sarcopenia / chemically induced
Sarcopenia / drug therapy*
Sarcopenia / pathology

Substances

Androgen Antagonists
Gonadotropin-Releasing Hormone